CHCallum J. Haseler

Callum J. Haseler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Callum J. Haseler has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Environmental impacts of equine parasiticide treatment: The UK perspective

    by Callum J. Haseler, Julia L. Shrubb, Hannah G. D. Davies, David I. Rendle, Polly C. Rathbone, Timothy S. Mair

    Summary: While there are limited data on the environmental impact of administering equine parasiticide drugs, evidence from other species indicates significant negative ecological effects. Anthelmintic drugs are excreted unchanged or metabolised to other active and/or toxic metabolites that enter the environment through direct excretion. These chemicals can have significant toxic effects on insects, such as dung beetles, earthworms and aquatic animals. Of the frequently used equine anthelmintics, ivermectin is the most ecotoxic; available evidence indicates that moxidectin is less toxic and fenbendazole appears to have little impact on dung‐colonising insects but may be toxic to aquatic organisms and fungi. There are little data regarding the ecotoxicity of pyrantel and praziquantel, although their ecotoxic effects are thought to be low. Pasture hygiene reduces pharmaceutical contamination and also helps to break the endoparasitic cycle of infectivity, thus reducing reliance on anthelmintics. Judicious and targeted use of endoparasiticides, along with pasture hygiene measures, will limit the ecotoxic effects of these drugs as well as reduce the selection pressure that drives anthelmintic resistance. Anthelmintics may also negatively impact the equine gastrointestinal microbiota. Ectoparasiticides (such as fipronil, permethrin and cypermethrin) may also have significant negative ecological effects, with a risk of contamination of both the immediate environment and water courses following topical use of these drugs. The half‐life of fipronil in the environment is variable, but it degrades into compounds which are more toxic; for example, it is highly toxic to bees and is reported to bioaccumulate in fish and can be toxic to birds. Of the synthetic pyrethroids, permethrin degrades at a faster rate than cypermethrin and may therefore have a lower ecotoxic effect. The ecotoxic effects of injectable doramectin are likely to be similar to oral ivermectin, although persistence in faeces may be significantly prolonged compared to the oral treatment route for ivermectin.


  • Open Access

    Environmental impacts of equine parasiticide treatment

    by Callum Haseler, Julia Shrubb, Hannah Davies, David Rendle, Polly Rathbone, Tim Mair

    Whilst there are limited data on the environmental impact of administering parasiticide drugs to horses, evidence from other species treated with identical drugs indicates significant negative ecological effects. Anthelmintic drugs may be excreted unchanged or metabolised to other active and/or toxic metabolites that enter the environment through direct excretion during grazing. These chemicals can have significant toxic effects on non-target insects, such as dung beetles, earthworms and aquatic animals. Of the anthelmintics frequently used in horses, ivermectin appears to be the most ecotoxic; available evidence indicates that moxidectin is less toxic. Fenbendazole appears to have little impact on dung-colonising insects but may be toxic to aquatic organisms and fungi. There is very little data regarding the ecotoxicity of pyrantel and praziquantel, although their ecotoxic effects are thought to be low. Pasture hygiene reduces pharmaceutical contamination and also helps to break the endoparasitic cycle of infectivity, thus reducing reliance on anthelmintics. Judicious use of endoparasiticides, along with pasture hygiene measures, will limit the ecotoxic effects of these drugs and reduce the selection pressure that drives anthelmintic resistance. Anthelmintics may also impact the equine gastrointestinal microbiota.Following topical treatment with ectoparasiticides (such as fipronil, permethrin or cypermethrin), there is a risk of contamination of both the immediate environment and water courses. The half-life of fipronil in the environment is variable, but it degrades into compounds which are more toxic; it is highly toxic to bees, and is reported to bioaccumulate in fish and can be toxic to birds. Of the synthetic pyrethroids, permethrin degrades at a faster rate than cypermethrin and may therefore have a lower ecotoxic effect. The ecotoxic effects of injectable doramectin are likely to be similar to oral ivermectin, although persistence in faeces may be significantly prolonged compared to the oral treatment route.

  • Sustainable development in equine anaesthesia

    by Callum J. Haseler, Eleanor West, Luís Filipe Louro, Ilaria Petruccione, Kate L. White, J. M. Tom Pierce

    Climate change is ‘the biggest global health threat of the 21st century’, and healthcare provision itself comes at an environmental cost. Volatile anaesthetic agents are potent greenhouse gases, but emissions arising from these waste anaesthetic gases can be dramatically reduced through a number of simple actions. This editorial lays out the options for more sustainable equine anaesthesia.


  • Open Access

    Sustainable development in equine anaesthesia

    by Callum Haseler, Ellie West, Luís Filipe Louro, Ilaria Petruccione, Kate White, J M Tom Pierce

    A document by Callum Haseler, written on Authorea.

  • Intrasynovial triamcinolone treatment is not associated with incidence of acute laminitis

    by Callum J. Haseler, Gavin E. Jarvis, Kate F. McGovern

    Background: Intrasynovial corticosteroid injections are commonly used in the treatment of equine orthopaedic disease, but corticosteroid administration is widely considered a risk factor for the development of laminitis. Despite a list of putative mechanisms and a number of case reports of steroid‐induced laminitis, no case‐control or cohort studies investigating the association between use of intrasynovial corticosteroids and acute laminitis have been published. Objectives: To quantify the risk of laminitis posed by intrasynovial triamcinolone acetonide (TA) administration in a mixed population of horses. Study design: Retrospective observational cohort study. Methods: Clinical records of horses registered with one large UK equine practice were reviewed retrospectively to identify all horses receiving intrasynovial TA treatment between 1 January 2007 and 31 December 2017. A total of 1510 horses were selected and records investigated for incidence of laminitis over a 4‐month period following treatment. For each TA‐treated horse, an untreated horse, individually matched by age, sex, date of treatment and client type, was selected from the clinical records. Untreated horses were then investigated for laminitis over the same 4‐month period. Data were analysed in a 2 × 2 contingency table using Fisher's exact test. Results: A total of 489 horses were lost to follow‐up and 55 horses were excluded, leaving 966 treated and matched, untreated horses. The incidence of laminitis over the 4‐month study period in both groups was identical: 3/966 horses (0.31%) (95% C.I. [0.08%, 0.91%]), equivalent to 0.93 cases per 100 horses per year ( P > .9). Main limitations: Retrospective study; large proportion (489/1510) of horses lost to follow‐up; large proportion of study population were racehorses; selection method resulted in disproportionate selection of horses born before 2013; similar incidence between groups may reflect existing risk‐based selection by clinicians. Conclusions: intrasynovial triamcinolone acetonide administration does not increase the risk of laminitis in this study population.